Shervin Khosousi
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease.
Journal: Movement disorders clinical practice
Published: July 10, 2025
Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: February 18, 2024
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease.
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease.
Journal: Translational neurodegeneration
Published: January 17, 2024
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.
Journal: Translational neurodegeneration
Published: April 14, 2023
Complement system changes in blood in Parkinson's disease and progressive Supranuclear Palsy/Corticobasal Syndrome.
Journal: Parkinsonism & related disorders
Published: June 14, 2022
Impaired migratory phenotype of CD4+ T cells in Parkinson's disease.
Journal: NPJ Parkinson's disease
Published: January 01, 2022
Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease.
Journal: Journal of Parkinson's disease
Published: September 17, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026